All In Biotech

Drug Trial Radar · NCT01218659

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT

Last checked: Nov 19, 2026Latest source record: Nov 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

68

Actual

Start

Sep 8, 2011

Primary completion

May 27, 2014

Study completion May 28, 2015

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT) in male and female participants with Fabry disease who are currently receiving ERT and who have an alpha galactosidase-A (α Gal-A) mutation that is amenable to migalastat, based on the clinical trial human embryonic kidney cell (HEK) assay.

Conditions

  • Fabry Disease

Interventions

  • migalastat hydrochlorideDrug

    150-mg capsule administered orally QOD

  • agalsidaseBiological

    Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration RateTime frame: Baseline to Month 18
  2. Annualized Rate Of Change From Baseline To Month 18 In eGFRTime frame: Baseline to Month 18

Locations

25 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Decatur, Georgia

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Fairfax, Virginia

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Perth, Western Australia, Australia

  • Site not named

    Vienna, Austria

  • Site not named

    Edegem, Belgium

  • Site not named

    São Paulo, Brazil

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Garches, France

  • Site not named

    Lille, France

  • Site not named

    Florence, Italy

  • Site not named

    Niigata, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Tokyo, Japan

  • Site not named

    Cambridge, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.